Citadel Advisors
TMCI icon

Citadel Advisors’s Treace Medical Concepts TMCI Stock Holding History

Citadel Advisors’s Portfolio TMCI Stock Details TMCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.06M Sell
516,994
-308,581
-37% -$848K ﹤0.01% 6483
2026
Q1 		$1.11M Buy
825,575
+613,669
+290% +$1.22M ﹤0.01% 7442
2025
Q4 		$519K Buy
+211,906
New +$920K ﹤0.01% 8946
2025
Q3 		– Sell
-59,230
Closed -$348K – 14119
2025
Q2 		$348K Sell
59,230
-212,042
-78% -$1.38M ﹤0.01% 9455
2025
Q1 		$2.28M Buy
271,272
+9,502
+4% +$85.4K ﹤0.01% 5294
2024
Q4 		$1.95M Buy
261,770
+191,230
+271% +$1.28M ﹤0.01% 5684
2024
Q3 		$409K Sell
70,540
-421,334
-86% -$2.71M ﹤0.01% 8689
2024
Q2 		$3.27M Buy
491,874
+427,755
+667% +$3.46M ﹤0.01% 4430
2024
Q1 		$837K Sell
64,119
-69,175
-52% -$922K ﹤0.01% 7307
2023
Q4 		$1.7M Buy
133,294
+7,337
+6% +$74.1K ﹤0.01% 5662
2023
Q3 		$1.65M Buy
125,957
+62,571
+99% +$1.15M ﹤0.01% 5564
2023
Q2 		$1.62M Sell
63,386
-498,726
-89% -$12.9M ﹤0.01% 5539
2023
Q1 		$14.2M Buy
562,112
+205,474
+58% +$4.82M ﹤0.01% 2342
2022
Q4 		$8.2M Buy
356,638
+203,216
+132% +$4.68M ﹤0.01% 3097
2022
Q3 		$3.39M Buy
153,422
+89,752
+141% +$1.74M ﹤0.01% 4564
2022
Q2 		$913K Sell
63,670
-41,646
-40% -$702K ﹤0.01% 7222
2022
Q1 		$1.99M Buy
105,316
+35,117
+50% +$683K ﹤0.01% 6091
2021
Q4 		$1.31M Sell
70,199
-58,894
-46% -$1.22M ﹤0.01% 7237
2021
Q3 		$3.47M Buy
129,093
+25,852
+25% +$711K ﹤0.01% 5049
2021
Q2 		$3.23M Buy
+103,241
New +$3.29M ﹤0.01% 5421

Other funds holding TMCI

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GA
Gagnon Advisors New York $157M AUM 36.77% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
CBU
CIBC Bancorp USA Chicago, Illinois $82.3B AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Citadel Advisors's TMCI Position: Q2 2026 in Review

Citadel Advisors reduced its Treace Medical Concepts (TMCI) stake by 37% in Q2 2026, selling an estimated $848K and leaving 516,994 shares worth $2.06M. The position accounts for ﹤0.01% of the portfolio, ranked #6483.

Citadel Advisors first reported a position in TMCI in Q2 2021 and has held it in 20 quarters since. The position peaked at $14.2M in Q1 2023. 117 funds tracked by Wall St. Rank hold TMCI as of Q2 2026.

  • Citadel Advisors held 516,994 shares of Treace Medical Concepts worth $2.06M as of Q2 2026.
  • Citadel Advisors sold 308,581 Treace Medical Concepts shares in Q2 2026, an estimated $848K.
  • Treace Medical Concepts made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #6483 holding.
  • Citadel Advisors first reported a position in Treace Medical Concepts in Q2 2021 and has held it in 20 quarters since.
  • Citadel Advisors's Treace Medical Concepts position peaked at $14.2M in Q1 2023.
  • 117 funds tracked by Wall St. Rank held Treace Medical Concepts as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.